Operon Insights

Subscription research for Life Science Tools and Diagnostics.

Deep-dive industry reports, proprietary financial models, and a weekly data-driven research report — all built on a stack of trackers Operon maintains continuously. For institutional investors and corporate decision-makers covering the sector.

What's inside
01

The Research Library

The library houses Operon's full body of published research. Subscribers receive new research on a regular cadence as it's published — never delayed, never tier-restricted within the library access they hold.

What's inside:

Every report is built on Operon's underlying data layer and is grounded in the trackers we maintain — not on narrative or consensus.

02

Proprietary Financial Models

Operon publishes two classes of financial models, available to subscribers at the appropriate access tiers.

Company-level models (Access and Elite) — full income statement, segment-level revenue build, margin walk, and forward forecasts for each name in our coverage. Models are updated as new data lands — earnings, guidance updates, end-market trackers, and industry events.

Market-level models (Elite only) — top-down market sizing and share models for the end markets and product categories we cover. Used by clients for diligence, scenario planning, and competitive intelligence.

03

The Signal

A weekly research report tracking the proprietary datasets that drive Operon's view of the industry — NIH funding flows, clinical trials activity, life sciences hiring, web traffic, and other public and licensed sources.

The Signal is detailed, timely, and decisive. It's the recurring deliverable subscribers can build their week around — and it's where the trackers behind every other Operon report come together in one place.

The data layer

Trackers, not narrative.

Operon's research is built on a continuously maintained stack of public and licensed datasets. Each tracker is designed to read against a specific industry question, and each report and model is grounded in this data layer before any analysis is written.

NIH Reporter & Outlays

Tracking federal research funding flows by institution, study section, and award category. A leading indicator of life sciences research activity and downstream tools and diagnostics demand.

Clinical Trials Activity

Trial starts, enrollment patterns, and sponsor activity across therapeutic areas. Reads against bioprocessing capacity, CRO demand, and downstream lab activity.

Life Sciences Hiring

Job postings data across life sciences companies and research institutions. A real-time signal on company-level investment and end-market demand.

Web Traffic

Traffic patterns for companies and platforms across the sector. Useful for early reads on product launches, tool adoption, and competitive share shift.

Plus public filings, public statements, third-party data providers, and industry channel checks.

Coverage

The Life Science Tools and Diagnostics value chain.

Life Science Tools

Instruments, consumables, and reagents across bioprocessing, NGS, mass spec, microscopy, and the broader bench.

Bioprocessing

Single-use and stainless infrastructure, cell culture media, fill-finish, and bioreactor capacity dynamics.

Next-Generation Sequencing

Platforms, consumables, and applications across clinical, research, and emerging segments.

Diagnostics (IVD and LDT)

Core lab automation, molecular diagnostics, point-of-care, and the regulatory landscape shaping LDT.

Lab Testing

Reference labs, hospital outreach, and the structural dynamics of the testing market.

Pharma Services

CROs, biomanufacturing capacity, and the contract services value chain.

What's new at Operon

No ratings. No price targets.

Operon publishes under the Investment Advisers Act publisher's exemption. Our focus is what drives industry growth and competitive share shift — not buy-sell-hold ratings.

Industry-driven, not consensus-driven.

Most sell-side coverage is shaped by what the Street already believes. Operon writes against that — focused on the trends and structural shifts that move industry growth, not on echoing the prevailing view.

Estimates that diverge when the data warrants.

Operon does not publish to consensus. When our forecasts differ from Street estimates and our trackers support the divergence, we publish them — that's where subscribers find the most value.

Get started

Three tiers. Three ways to start.

Read the work.

A representative report from Operon's library, made available without subscription.

Read the sample

See the tiers.

Pricing, what's included at each level, and how subscriptions work.

See pricing

Talk to us.

Have questions, need enterprise terms, or want to discuss Elite-tier access?

Contact us